Point72 Asset Management
TERN

Point72 Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

Point72 Asset Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-573,700
Closed -$23.6M – 4492
2025
Q4 		$23.2M Buy
+573,700
New +$13.3M 0.03% 789
2025
Q2 		– Sell
-160,725
Closed -$444K – 2608
2025
Q1 		$444K Sell
160,725
-1,091,116
-87% -$4.46M ﹤0.01% 1657
2024
Q4 		$6.94M Sell
1,251,841
-1,455,674
-54% -$9.86M 0.02% 840
2024
Q3 		$22.6M Buy
2,707,515
+17,139
+0.6% +$141K 0.06% 383
2024
Q2 		$18.3M Buy
2,690,376
+469,176
+21% +$2.84M 0.05% 421
2024
Q1 		$14.6M Buy
+2,221,200
New +$14.5M 0.04% 568
2023
Q4 		– Sell
-571,265
Closed -$2.87M – 2809
2023
Q3 		$2.87M Buy
+571,265
New +$3.63M 0.01% 1043
2023
Q2 		– Sell
-629,098
Closed -$7.45M – 2777
2023
Q1 		$7.45M Buy
629,098
+395,598
+169% +$3.78M 0.02% 639
2022
Q4 		$2.38M Buy
+233,500
New +$1.55M 0.01% 909
2022
Q3 		– Sell
-500,000
Closed -$1.24M – 1727
2022
Q2 		$1.24M Buy
500,000
+377,427
+308% +$754K 0.01% 1029
2022
Q1 		$364K Buy
+122,573
New +$523K ﹤0.01% 1037

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Point72 Asset Management's TERN Position: Q1 2026 in Review

Point72 Asset Management sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 573,700 shares — an estimated $23.6M sold.

Point72 Asset Management first reported a position in TERN in Q1 2022 and held it in 11 quarters. The position peaked at $23.2M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Point72 Asset Management reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 573,700 Terns Pharmaceuticals shares in Q1 2026, an estimated $23.6M.
  • Point72 Asset Management first reported a position in Terns Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • Point72 Asset Management's Terns Pharmaceuticals position peaked at $23.2M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.